Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications
about
Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonistsA key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administrationDifferential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in miceDesigning bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.The Nociceptin Receptor as an Emerging Molecular Target for Cocaine AddictionThe first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mousNociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.Retrodialysis of N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular dopamine and locomotor activityNociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory painCentral N/OFQ-NOP Receptor System in Pain Modulation.Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.Preclinical evidence of new opioid modulators for the treatment of addiction.Opioid system and Alzheimer's disease.Opioid receptor targeting ligands for pain management: a review and update.Where do we stand in the field of anti-abuse drug discovery?Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptomsTargeting multiple opioid receptors - improved analgesics with reduced side effects?Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.A novel and selective nociceptin receptor (NOP) agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) decreases acquisition of ethanol-induced conditioned place preference in mice.Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.
P2860
Q26852027-C39A5D8C-FB9C-4E45-9767-EBE9219D4273Q27312608-0750ABF5-E46A-4FF7-A55B-E360E5315A38Q28246174-932EF488-823D-4B70-9492-072DF62412DEQ33662208-512E9C10-4C43-46A1-8527-495B7D031AA1Q34510753-CE8F69CE-047D-4836-91DE-90102D84070BQ34702273-B34EF167-F0CC-4C02-9B03-E5138087B3ABQ36521971-E1D193D7-9C12-449A-9377-88B26C4B1062Q36603205-4303DB1C-1C90-4A5E-A149-43279205893DQ36605104-85CBCC29-4AA4-4AFE-978E-DF3FC1D8C184Q36744366-FDB00296-4F6B-495E-8468-24B5DB69AB2DQ36935325-4B10ABB7-A31C-4AF3-8AE6-233D8F167978Q37094760-838FC8FF-63F3-42A3-84FC-B61A5204BDDBQ37211503-5CD94E70-FA71-4352-8E95-3F32AEC20437Q37444462-38D26C9B-DC97-417F-9683-8616066B6B18Q37679197-A4E45180-4044-4D5C-B85C-B952B5DC4D33Q37772519-7309D2B3-B2CD-44DD-A0F2-616265F9D5E3Q38004941-9C451F41-7D9A-40A6-B9DC-D27B6E290FC0Q38028661-90A99888-C42A-4F04-B0D8-CEB08B60C583Q38243888-7FDA12B7-0079-4D30-B66B-4453F70730A6Q38716082-39A8A4A1-B41A-4120-B35B-2071035E9416Q38990121-1E9B558D-ED34-470B-B51F-DD734F7D4BCAQ39194989-5E5D87E0-D618-41B1-A48E-5D5B645AF091Q39221109-C37E31E9-B8E9-4A7E-A6A2-F48DBABD2B4DQ40620939-212EF6DE-9671-46AA-B6E2-20F93AC15752Q42378885-23C122B1-6EA0-40F2-9B8E-ADE9197933ACQ43165858-182F509E-7E98-4CCE-A826-26B0627364A5Q45998228-4817BA27-C30B-4905-B1B4-25BC9FA5279EQ46101192-B1E76A5E-635B-454C-8CEF-74922304AE9CQ55022470-0D4666C7-DEE7-4AA8-B8E2-3C855926399C
P2860
Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of the antinocicept ...... s for therapeutic applications
@en
Comparison of the antinocicept ...... for therapeutic applications.
@nl
type
label
Comparison of the antinocicept ...... s for therapeutic applications
@en
Comparison of the antinocicept ...... for therapeutic applications.
@nl
prefLabel
Comparison of the antinocicept ...... s for therapeutic applications
@en
Comparison of the antinocicept ...... for therapeutic applications.
@nl
P2093
P2860
P356
P1476
Comparison of the antinocicept ...... s for therapeutic applications
@en
P2093
Cris Olsen
Faming Jiang
Lawrence Toll
Nurulain T Zaveri
Taline V Khroyan
Willma E Polgar
P2860
P304
P356
10.1124/JPET.109.157446
P407
P577
2009-09-22T00:00:00Z